Sungkyunkwan University · 医学
Professor Seok Jin Kim's research lab specializes in hematologic malignancies, with a primary focus on extranodal natural killer/T-cell lymphoma (ENKTL) and diffuse large B-cell lymphoma (DLBCL). The lab investigates optimal treatment strategies, including chemotherapy, radiotherapy, and immunotherapy, with particular emphasis on the role of surgery and immune checkpoint inhibitors like avelumab in improving survival and quality of life. The lab also explores predictive biomarkers such as CA IX and PD-L1 expression to guide personalized therapy in lymphomas and non-small cell lung cancer.
Figures are computed from collected data and may differ slightly.
Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.
The aim of this retrospective cohort study was to analyze the impact of surgery on the outcomes and qualities of life (QOL) in patients with intestinal diffuse large B-cell lymphoma (DLBCL). We assessed 345 patients with either localized or disseminated intestinal DLBCL and compared them according to treatment: surgical resection followed by chemotherapy versus chemotherapy alone. In patients with localized disease (Lugano stage I/II), surgery plus chemotherapy yielded a lower relapse rate (15.3
The survival of patients with ileocecal region involvement was better than that of patients with involvement at other sites, which might be related to histologic distribution, the proportion of tumor stage, and need for surgical resection.
This study aimed to assess the efficacy and safety of treatment with avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL). In this phase 2 trial, 21 patients with relapsed or refractory ENKTL were treated with 10 mg/kg of avelumab on days 1 and 15 of a 28-day cycle. The primary end point was the complete response (CR) rate based on the best response. Targeted sequencing and immunohistochemistry wer
CA IX expression of tumor cells may be an indicator for poor disease-free survival in early-stage NSCLC.
Overall, the data indicated that ENKTL involving the GI tract has a dismal prognosis despite active treatment including chemotherapy and surgery. Thus, more effective treatment strategies are required for this disease entity.
Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses.
Open papers in the app to read, cite, and organize with AI.
